Phenotypic Spectrum of Type 2-3 Gaucher Disease: A Case Study in the Balkan Genotype
Open Access
- 15 January 2026
- journal article
- case report
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e948999
Abstract
BACKGROUND Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the glucosylceramidase beta 1 (GBA1) gene, with a wide range of clinical manifestations. Type 2 GD, the acute neuronopathic form, is the most severe and has historically been considered a distinct clinical entity. Emerging evidence suggests a broader phenotypic spectrum, including intermediate forms that do not fully align with the diagnostic criteria for either type 2 or type 3 GD. Here, we describe an Albanian patient with an unusual intermediate type 2-3 phenotype, homozygous for the rare GBA1 complex allele p.[His294Gln;Asp448His] that is frequently found in Balkan populations. Although this genotype is typically associated with early-onset type 2 GD and death within the first 2 years of life, our patient developed neurologic symptoms at 15 months and survived until age 5. CASE REPORT A male Albanian infant presented at 4 months of age with hepatosplenomegaly and thrombocytopenia. Genetic testing revealed homozygosity for the rare GBA1 complex allele p.[His294Gln;Asp448His]. Enzyme replacement therapy, initiated at 7 months, led to temporary improvement of visceral and hematological symptoms. Neurologic manifestations - including oculomotor apraxia, dystonia, and seizures - emerged at 15 months. Despite continued enzyme replacement therapy and supportive care, the patient's neurologic condition progressively worsened, and he died at age 5 due to disease progression and pulmonary complications. CONCLUSIONS This case reinforces the concept that type 2 GD exists on a phenotypic spectrum, rather than as a uniform clinical entity, and underscores the broad genotype-phenotype variability in GD.Keywords
This publication has 29 references indexed in Scilit:
- Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneityBlood Cells, Molecules, and Diseases, 2011
- Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher DiseaseJournal of Biological Chemistry, 2009
- Glucocerebrosidase mutation H255Q appears to be exclusively in cis with D409H: structural implicationsClinical Genetics, 2009
- Haplotype analysis suggests a single Balkan origin for the Gaucher disease [D409H;H255Q] double mutant alleleHuman Mutation, 2008
- Homozygosity for the double D409H+H255Q allele in type II Gaucher diseaseJournal of Inherited Metabolic Disease, 2006
- Type 2 Gaucher disease: 15 new cases and review of the literatureBrain and Development, 2006
- Divergent phenotypes in Gaucher disease implicate the role of modifiersJournal of Medical Genetics, 2005
- Homozygosity for a non-pseudogene complex glucocerebrosidase allele as cause of an atypical neuronopathic form of Gaucher diseaseAmerican Journal of Medical Genetics Part A, 2005
- Phenotypic continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3The Journal of Pediatrics, 2003
- Glucocerebrosidase gene mutations in patients with type 2 Gaucher diseaseHuman Mutation, 2000